The HR trends for PFS per investigator assessment and BICR were similar; per investigator assessment, NIVO + IPI showed PFS benefit versus Chemo in patients with tumor-cell PD-L1 ≥ 1% (5.4 vs. 3.0 months; HR 0.57 [0.38–0.87]) and was comparable with Chemo in all randomized patients (4.1 vs. 4.2 months; HR 0.84 [0.64–1.11]) (Online Resource 4). The gene discussed is CD274; the disease is neoplasm.